Who is sponsoring NCT04903782?

NCT04903782 is sponsored by Sydney Children's Hospitals Network.

What drugs are being tested in NCT04903782?

Interventions in NCT04903782: Family-based whole genome sequencing.

What condition does NCT04903782 study?

NCT04903782 studies Neoplastic Syndromes, Hereditary, Cancer, Genetic Predisposition to Disease.

Is NCT04903782 still recruiting?

NCT04903782 is currently recruiting now. Last updated 4 November 2022.

Last reviewed 2022-11-04 · How we verify

NCT04903782: PREDICT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer

Recruiting now Last updated 4 November 2022

What this trial tests

trial testing Family-based whole genome sequencing in Neoplastic Syndromes, Hereditary in 270 participants. Currently enrolling.

Timeline

8 March 2021

Primary endpoint
8 March 2023

15 June 2028

Quick facts

Lead sponsor	Sydney Children's Hospitals Network
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	270
Start date	8 March 2021
Primary completion	8 March 2023
Estimated completion	15 June 2028
Sites	3 locations across Australia

Drugs / interventions tested

Family-based whole genome sequencing

Conditions studied

Neoplastic Syndromes, Hereditary — all drugs for Neoplastic Syndromes, Hereditary →
Cancer — all drugs for Cancer →
Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →

Sponsor

Sydney Children's Hospitals Network

Who can join

Under 21, any sex, with Neoplastic Syndromes, Hereditary or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of the utility of family-based (trio) whole-genome sequencing for cancer predisposition testing in sequential newly diagnosed paediatric and adolescent cancer patients

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Protocol for a comprehensive prospective cohort study of trio-based whole-genome sequencing for underlying cancer predisposition in paediatric and adolescent patients newly diagnosed with cancer: the PREDICT study.
Fuentes Bolanos NA, Padhye B, Daley M, Hunter J, et al · · 2023 · cited 5× · PMID 37253493 · DOI 10.1136/bmjopen-2022-070082

Verify or expand the search:

Other Sydney Children's Hospitals Network trials

Trials by the same sponsor.

NCT03530813 — Role of Technology in Improving Asthma Management In School Staff · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04903782 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sydney Children's Hospitals Network
Last refreshed: 4 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04903782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing